We are live on ! Find out more
Bellevue Group

Bellevue Group Portfolio holdings

AUM $4.82B Turnover 23.39%
1-Year Est. Return 53.85%
 

Bellevue Group is a Swiss asset manager that focuses on healthcare investing, small and mid-cap companies and other growth strategies. Martin Bisang and four other founders started it in 1993, and through its subsidiary Bank am Bellevue it first became a major name in brokerage and block trading on the Swiss market. It sold that bank to Luxembourg's KBL Group in 2019, dropping its private client business and becoming a pure asset manager. In 2016 it bought the German asset manager StarCapital to build its presence in Germany, and in 2023 it launched Bellevue Obesity Solutions, a global equity fund.

This Fund
S&P 500
This Quarter Est. Return
-6.91%
1 Year Est. Return
+53.85%
3 Year Est. Return
+187.03%
5 Year Est. Return
+202.92%
10 Year Est. Return
+987.38%
AUM
$488M
AUM Growth
-$65.2M
Cap. Flow
-$17.8M
Cap. Flow %
-3.65%
Top 10 Hldgs %
32.78%
Holding
126
New
4
Increased
19
Reduced
35
Closed
4
Avg Time Held
0.7 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.6 years

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$5.8M
2
INCY icon
Incyte
INCY
+$5.8M
3
BCR
CR Bard
BCR
+$5.67M
4
AKRX
Akorn Inc
AKRX
+$4.79M
5
EW icon
Edwards Lifesciences
EW
+$3.89M

Top Sells

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$6.82M
2
ILMN icon
Illumina
ILMN
+$5.64M
3
AMSG
Amsurg
AMSG
+$4.79M
4
SYK icon
Stryker
SYK
+$2.92M
5
CI icon
Cigna
CI
+$2.88M

Sector Composition

Rank Sector Weight
1 Healthcare 98.51%
2 Miscellaneous 1.07%
3 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CELG
1
DELISTED
Celgene
CELG
$23.1M 4.73%
199,650
+5,400
+3% +$601K
2016 Q1
3 quarters
SYK icon
2
Stryker
SYK
$121B
$18.6M 3.81%
155,400
-25,400
-14% -$2.92M
2016 Q1
3 quarters
MDT icon
3
Medtronic
MDT
$132B
$18.5M 3.79%
259,500
+12,000
+5% +$943K
2016 Q1
3 quarters
UNH icon
4
UnitedHealth
UNH
$355B
$17.6M 3.61%
110,000
+10,800
+11% +$1.61M
2016 Q1
3 quarters
ABT icon
5
Abbott
ABT
$183B
$15.6M 3.19%
405,500
+21,500
+6% +$853K
2016 Q1
3 quarters
INCY icon
6
Incyte
INCY
$24.7B
$15.1M 3.09%
150,400
+59,400
+65% +$5.8M
2016 Q1
3 quarters
BIIB icon
7
Biogen
BIIB
$37.2B
$13.9M 2.85%
49,000
-5,500
-10% -$1.63M
2016 Q1
3 quarters
GILD icon
8
Gilead Sciences
GILD
$212B
$12.9M 2.63%
179,500
+23,000
+15% +$1.71M
2016 Q1
3 quarters
LGND icon
9
Ligand Pharmaceuticals
LGND
$5.92B
$12.7M 2.59%
199,622
+28,293
+17% +$1.79M
2016 Q1
3 quarters
AMGN icon
10
Amgen
AMGN
$249B
$12.2M 2.5%
83,500
– –
2016 Q1
3 quarters
BSX icon
11
Boston Scientific
BSX
$62.6B
$11.9M 2.44%
550,000
-25,000
-4% -$545K
2016 Q1
3 quarters
REGN icon
12
Regeneron Pharmaceuticals
REGN
$100B
$11.9M 2.43%
32,300
-5,700
-15% -$2.17M
2016 Q1
3 quarters
EW icon
13
Edwards Lifesciences
EW
$61.2B
$11.7M 2.4%
375,000
+120,000
+47% +$3.89M
2016 Q1
3 quarters
BCR
14
DELISTED
CR Bard
BCR
$11.5M 2.35%
51,100
+26,100
+104% +$5.67M
2016 Q1
3 quarters
ZBH icon
15
Zimmer Biomet
ZBH
$19.5B
$10.6M 2.18%
106,090
+23,690
+29% +$2.54M
2016 Q1
3 quarters
AKRX
16
DELISTED
Akorn Inc
AKRX
$10M 2.06%
460,000
+208,000
+83% +$4.79M
2016 Q2
2 quarters
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$15.5B
$9.14M 1.87%
83,800
– –
2016 Q1
3 quarters
VTRS icon
18
Viatris
VTRS
$23.7B
$8.99M 1.84%
235,700
– –
2016 Q1
3 quarters
HOLX icon
19
DELISTED
Hologic
HOLX
$8.81M 1.8%
219,600
-22,500
-9% -$868K
2016 Q1
3 quarters
CNC icon
20
Centene
CNC
$36.4B
$8.57M 1.75%
303,260
+20,400
+7% +$602K
2016 Q1
3 quarters
TEVA icon
21
Teva Pharmaceutical Industries
TEVA
$49.3B
$8.52M 1.74%
234,990
+47,800
+26% +$1.91M
2016 Q1
3 quarters
BAX icon
22
Baxter International
BAX
$13.4B
$8.42M 1.73%
190,000
– –
2016 Q1
3 quarters
ILMN icon
23
Illumina
ILMN
$30.4B
$6.89M 1.41%
55,306
-41,814
-43% -$5.64M
2016 Q1
3 quarters
BDX icon
24
Becton Dickinson
BDX
$58.8B
$6.62M 1.36%
41,000
-15,375
-27% -$2.55M
2016 Q1
3 quarters
AGN
25
DELISTED
Allergan plc
AGN
$6.17M 1.26%
29,400
– –
2016 Q2
2 quarters

Similar funds

Bellevue Group's Q4 2016 Portfolio in Review

As of Q4 2016, Bellevue Group held 126 positions worth $488M, down 12% from $553M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group withdrew a net $17.8M in Q4 2016, closing 4 positions and reducing 35 holdings. Its most notable exit was Amsurg, an estimated $4.79M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Bellevue Group opened a new position in Danaher worth $5.76M.

  • Bellevue Group's largest Q4 2016 buy was Danaher: 83,472 shares worth $5.76M.
  • Bellevue Group added most to Incyte in Q4 2016, an estimated $5.8M increase.
  • Bellevue Group's biggest Q4 2016 reduction was Cardinal Health, cutting an estimated $6.82M.
  • Bellevue Group fully exited Amsurg in Q4 2016, selling an estimated $4.79M.
  • Bellevue Group's ten largest holdings make up 33% of its $488M portfolio in Q4 2016.
  • Bellevue Group opened 4 new positions and closed 4 in Q4 2016.
  • Bellevue Group's portfolio value fell 12% quarter-over-quarter to $488M.

Based on Bellevue Group's 13F filing for Q4 2016, filed 10 Feb 2017.